Westchester Capital Management (New York)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Westchester Capital Management (New York)’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-793,349	Closed	-$32.4M	–	241
2024 Q2	$32.4M	Buy	793,349 +45,755	+6%	+$1.91M	1.22%	21
2024 Q1	$31.6M	Buy	747,594 +18,284	+3%	+$768K	1.16%	18
2023 Q4	$30.9M	Buy	+729,310	New	+$21M	1.08%	23

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Westchester Capital Management (New York)'s CERE Position: Q3 2024 in Review

Westchester Capital Management (New York) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 793,349 shares — an estimated $32.4M sold.

Westchester Capital Management (New York) first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $32.4M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Westchester Capital Management (New York) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Westchester Capital Management (New York) sold 793,349 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $32.4M.
Westchester Capital Management (New York) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
Westchester Capital Management (New York)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $32.4M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.